Contributions in the domain of cancer research: Review¶Negative regulators of cyclin-dependent kinases and their roles in cancers

Abstract: In the past decade, the discovery and characterization of cyclin-dependent kinases (CDKs), the engine cores of the cell cycle machinery, have advanced our understanding of the cell cycle. Both positive and negative regulators of CDKs have been characterized, accelerating the important research to unravel the mechanisms of the cell cycle disease - cancer. Cancer can originate from overexpression of positive regulators, such as cyclins, or from underexpression of negative regulators, such as CDK inhibitors (CKIs). CKIs are the focus of much cancer research because they are capable of controlling cell cycle proliferation - the Holy Grail for cancer treatment. CDKs can be inactivated by several mechanisms:, (i) by association with CKIs including p16 (INK4a), p15 (INK4b), p21 (Cip1), p27 (Kip1), and p57 (Kip2), (ii) by disassociation from their cyclin regulatory unit, (iii) by dephosphorylation of a conserved threonine residue in the T-loop, and (iv) by adding inhibitory phosphate. Here we discuss what is known about each mechanism with a hope that these insights will become useful in developing strategies to eliminate cancer in the future.

[1]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[2]  B. Amati,et al.  Growth arrest by the cyclin‐dependent kinase inhibitor p27Kip1 is abrogated by c‐Myc. , 1996, The EMBO journal.

[3]  W. Ansorge,et al.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.

[4]  C. Turck,et al.  Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit , 1993, Nature.

[5]  L. Soucek,et al.  Making decisions through Myc , 2001, FEBS letters.

[6]  S. Okret,et al.  p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. , 1999, Molecular endocrinology.

[7]  D. Stokoe,et al.  p27Kip1 is required for PTEN-induced G1 growth arrest. , 2001, Cancer Research.

[8]  J. Nesland,et al.  Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.

[9]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[10]  J. Palazzo,et al.  Inhibitor p27 in Epithelial Ovarian Cancer Frequent Loss of Expression of the Cyclin-dependent Kinase , 1999 .

[11]  W. Gerald,et al.  Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors. , 1996, Cancer research.

[12]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[13]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[14]  V. P. Collins,et al.  Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[15]  I. Hampson,et al.  Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). , 1999, Genes & development.

[16]  J. Mestan,et al.  Skp2 is oncogenic and overexpressed in human cancers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Jónasson,et al.  Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival , 1999, British Journal of Cancer.

[18]  T. Pandita,et al.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. S. Kim,et al.  Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. , 2000, Cancer research.

[20]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[21]  B. Wiedenmann,et al.  A Novel Function for the Tumor Suppressor p16INK4a , 2000, The Journal of Cell Biology.

[22]  K. Kinzler,et al.  14-3-3σ is required to prevent mitotic catastrophe after DNA damage , 1999, Nature.

[23]  James M. Roberts,et al.  The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.

[24]  R. Liang,et al.  Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Reiss,et al.  Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. , 1995, Gene.

[26]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[27]  A. Kumagai,et al.  Positive Regulation of Wee 1 by Chk 1 and 14-3-3 Proteins , 2001 .

[28]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[29]  B. Amati.  Integrating Myc and TGF-β signalling in cell-cycle control , 2001, Nature Cell Biology.

[30]  S. Elledge,et al.  p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells , 1995, Science.

[31]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[32]  S. Sakaki,et al.  Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. , 1999, Cancer research.

[33]  F. McKeon,et al.  Tyrosine kinases wee1 and mik1 as effectors of DNA replication checkpoint control. , 1996, Progress in cell cycle research.

[34]  G. Peters,et al.  Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.

[35]  H. Piwnica-Worms,et al.  The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex , 1997, Molecular and cellular biology.

[36]  A. Cittadini,et al.  Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  Jong-Yeon Shin,et al.  Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer , 2000, Experimental & Molecular Medicine.

[38]  A. Kumagai,et al.  Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. , 2001, Molecular biology of the cell.

[39]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[40]  Jianxiang,et al.  In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. , 1995, Cancer research.

[41]  J. Lammers,et al.  Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27KIP1 , 2000, Molecular and Cellular Biology.

[42]  M. Hung,et al.  Correlation of p27 protein expression with HER‐2/neu expression in breast cancer , 2001, Molecular carcinogenesis.

[43]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[44]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[45]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[46]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[47]  P. Yaswen,et al.  p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. , 1999, Cancer research.

[48]  A. Sewing,et al.  Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.

[49]  D. Coppola,et al.  CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. , 2001, Cancer research.

[50]  I. Hoffmann,et al.  Cell cycle regulation by the Cdc25 phosphatase family. , 2000, Progress in cell cycle research.

[51]  M. Nistér,et al.  Induction of senescence in human malignant glioma cells by p16INK4A , 1997, Oncogene.

[52]  J. Massagué,et al.  Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  W. Schulz,et al.  Decreased expression of p57KIP2mRNA in human bladder cancer , 2000, British Journal of Cancer.

[54]  Xiao-Fan Wang,et al.  Functional Analysis of the Transforming Growth Factor βResponsive Elements in the WAF1/Cip1/p21 Promoter (*) , 1995, The Journal of Biological Chemistry.

[55]  Y. Liaw,et al.  Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. , 2000, Cancer research.

[56]  R. Fåhraeus,et al.  The p16INK4a tumour suppressor protein inhibits αvβ3 integrin‐mediated cell spreading on vitronectin by blocking PKC‐dependent localization of αvβ3 to focal contacts , 1999 .

[57]  A. Fattaey,et al.  Myt1: a Wee1-type kinase that phosphorylates Cdc2 on residue Thr14. , 1997, Progress in cell cycle research.

[58]  G. Peters,et al.  Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence , 2001, Nature.

[59]  D. Alberts,et al.  Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. , 1996, Cancer genetics and cytogenetics.

[60]  T. Ørntoft,et al.  Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. , 1997, Cancer research.

[61]  A. Kamb,et al.  Cell-cycle regulators and cancer. , 1995, Trends in genetics : TIG.

[62]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[63]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[64]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[65]  O. Bachs,et al.  The Protein SET Regulates the Inhibitory Effect of p21Cip1 on Cyclin E-Cyclin-dependent Kinase 2 Activity* , 1999, The Journal of Biological Chemistry.

[66]  J. Bartek,et al.  Aberrant p27Kip1 promoter methylation in malignant melanoma , 2000, Oncogene.

[67]  Roger Brent,et al.  C dil, a Human Gl and S Phase Protein Phosphatase That Associates with Cdk2 , 2003 .

[68]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[69]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[70]  J. R. Smith,et al.  Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. , 1994, Experimental cell research.

[71]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[72]  K. Mimori,et al.  p27 expression and gastric carcinoma , 1997, Nature Medicine.

[73]  M. Kitagawa,et al.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication , 2000, The EMBO journal.

[74]  E. Nabel,et al.  The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo , 1995, Nature Medicine.

[75]  Jeffrey E. Green,et al.  Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21 , 2001, Cancer Gene Therapy.

[76]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[77]  R. Parsons,et al.  PTEN: life as a tumor suppressor. , 2001, Experimental cell research.

[78]  J. Herman,et al.  p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. , 1999, Blood.

[79]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[80]  G. Hannon,et al.  Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). , 1995, Cytogenetics and cell genetics.

[81]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[82]  R. Mamillapalli,et al.  PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27KIP1 through the ubiquitin E3 ligase SCFSKP2 , 2001, Current Biology.

[83]  C. Cordon-Cardo,et al.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. , 1999, Journal of the National Cancer Institute.

[84]  Stuart A. Aaronson,et al.  Overexpression of Kinase-Associated Phosphatase (KAP) in Breast and Prostate Cancer and Inhibition of the Transformed Phenotype by Antisense KAP Expression , 2000, Molecular and Cellular Biology.

[85]  G. Hannon,et al.  Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD , 1995, Science.

[86]  K. Kinzler,et al.  14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. , 1999, Nature.

[87]  James M. Roberts,et al.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.

[88]  E Ruoslahti,et al.  Integrins and anoikis. , 1997, Current opinion in cell biology.

[89]  R. DePinho,et al.  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Marshall,et al.  The role of αv-integrins in tumour progression and metastasis , 1996 .

[91]  N. Heisterkamp,et al.  Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. , 2000, Blood.

[92]  R. Klausner,et al.  The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[93]  R. Kratzke,et al.  Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus , 2000, Cancer Gene Therapy.

[94]  Wilhelm Krek,et al.  p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells , 1999, Nature Cell Biology.

[95]  J. Kato,et al.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.

[96]  M. Hung,et al.  Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27* , 2000, The Journal of Biological Chemistry.

[97]  C. O'keefe,et al.  Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. , 1996, Molecular biology of the cell.

[98]  M. Steiner,et al.  Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence , 2000, Cancer Gene Therapy.

[99]  U. Mansmann,et al.  Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array , 1999, International journal of cancer.

[100]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[101]  M. Roussel,et al.  Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.

[102]  E. Pérez-Payá,et al.  Calmodulin Binds to p21Cip1 and Is Involved in the Regulation of Its Nuclear Localization* , 1999, The Journal of Biological Chemistry.

[103]  R. Weksberg,et al.  Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. , 2000, The American journal of pathology.

[104]  Mong-Hong Lee,et al.  Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression* , 2000, The Journal of Biological Chemistry.

[105]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[106]  R. Hruban,et al.  High‐resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus region at 1p35 , 1999, Genes, chromosomes & cancer.

[107]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[108]  M. Cleary,et al.  Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. , 1999, Genes & development.

[109]  S. Natsugoe,et al.  p21 expression is a prognostic factor in patients with p53-negative gastric cancer. , 2000, Cancer letters.

[110]  L. Hengst,et al.  Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication , 1998, Molecular and Cellular Biology.

[111]  M. Toyota,et al.  Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. , 2000, Cancer research.

[112]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[113]  J. Massagué,et al.  TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b , 2001, Nature Cell Biology.

[114]  I. Wong,et al.  Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.

[115]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[116]  F. Sarkar,et al.  Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer. , 1998, Cancer gene therapy.

[117]  D. Sidransky,et al.  p16(MTS-1/CDKN2/INK4a) in cancer progression. , 2001, Experimental cell research.

[118]  A. Koff,et al.  Cell-cycle inhibitors: three families united by a common cause. , 2000, Gene.

[119]  Ling He,et al.  Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. , 2000, Cancer research.

[120]  S. Seeber,et al.  Expression of p21WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  Q. Li,et al.  Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. , 1998, Biochemical and biophysical research communications.

[122]  岩田 徳和.  Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 σ gene in human hepatocellular carcinoma , 2001 .

[123]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[124]  M. Malumbres,et al.  Cellular Response to Oncogenic Ras Involves Induction of the Cdk4 and Cdk6 Inhibitor p15INK4b , 2000, Molecular and Cellular Biology.

[125]  S. Elledge,et al.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. , 1995, Genes & development.

[126]  L. Reid,et al.  Genomic organization of the human p57KIP2 gene and its analysis in the G401 Wilms' tumor assay. , 1996, Cancer research.

[127]  M. Leibovitch,et al.  Stabilization of MyoD by Direct Binding to p57Kip2 * , 2000, The Journal of Biological Chemistry.

[128]  T. Coleman,et al.  Myt1: A Membrane-Associated Inhibitory Kinase That Phosphorylates Cdc2 on Both Threonine-14 and Tyrosine-15 , 1995, Science.

[129]  J. Roth,et al.  Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. , 1996, Cancer gene therapy.

[130]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[131]  J. Xiang,et al.  Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth , 2000, Cancer Gene Therapy.

[132]  J. Massagué,et al.  Repression of p15INK4b expression by Myc through association with Miz-1 , 2001, Nature Cell Biology.

[133]  A. Fattaey,et al.  Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity* , 1997, The Journal of Biological Chemistry.

[134]  Raymond White,et al.  Characterization of colonic polyps by two‐dimensional gel electrophoresis , 1999, Electrophoresis.

[135]  R. Medema,et al.  AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.

[136]  E. Dellambra,et al.  Stratifin, a keratinocyte specific 14-3-3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. , 1995, Journal of cell science.

[137]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[138]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[139]  R. Medema,et al.  p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases , 1998, Oncogene.

[140]  M. Ivan,et al.  The von Hippel-Lindau tumor suppressor protein. , 2001, Current opinion in genetics & development.

[141]  Andrea C. Carrano,et al.  SKP 2 is required for ubiquitin-mediated degradation of the CDK inhibitor p 27 , 1999 .

[142]  A. Ferguson-Smith,et al.  Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[143]  R. Kobayashi,et al.  pl9 skp1 and p45 skp2 are essential elements of the cyclin A-CDK2 S phase kinase , 1995, Cell.

[144]  D. W. Kim,et al.  Repression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc , 2001, Oncogene.

[145]  N. Rhind,et al.  Regulation of Mitotic Inhibitor Mik1 Helps to Enforce the DNA Damage Checkpoint , 2000, Molecular biology of the cell.

[146]  Y. Fukushima,et al.  An imprinted gene p57KIP2 is mutated in Beckwith–Wiedemann syndrome , 1996, Nature Genetics.

[147]  K. Miyazono,et al.  Smad-mediated Transcription Is Required for Transforming Growth Factor-β1-induced p57Kip2 Proteolysis in Osteoblastic Cells* , 2001, The Journal of Biological Chemistry.

[148]  J. Gutterman,et al.  Retardation of cell proliferation after expression of p202 accompanies an increase in p21(WAF1/CIP1). , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[149]  M. Leibovitch,et al.  p57Kip2 Stabilizes the MyoD Protein by Inhibiting Cyclin E-Cdk2 Kinase Activity in Growing Myoblasts , 1999, Molecular and Cellular Biology.

[150]  E. Valverius,et al.  Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[151]  S. Reed,et al.  Nuclear Accumulation of p21Cip1 at the Onset of Mitosis: a Role at the G2/M-Phase Transition , 1998, Molecular and Cellular Biology.

[152]  M. Barbacid,et al.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. , 1997, Genes & development.

[153]  Hong Sun,et al.  PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[154]  S. R. Hann,et al.  A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[155]  M. Pagano,et al.  Role of the F-box protein Skp2 in lymphomagenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[156]  D. Givol,et al.  Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.

[157]  P. Lengyel,et al.  p202, an Interferon-inducible Modulator of Transcription, Inhibits Transcriptional Activation by the p53 Tumor Suppressor Protein, and a Segment from the p53-binding Protein 1 That Binds to p202 Overcomes This Inhibition* , 1996, The Journal of Biological Chemistry.